InspireMD Inc
NASDAQ:NSPR

Watchlist Manager
InspireMD Inc Logo
InspireMD Inc
NASDAQ:NSPR
Watchlist
Price: 1.65 USD
Market Cap: $69.9m

Net Margin

-593.8%
Current
Declining
by 174.3%
vs 3-y average of -419.6%

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-593.8%
=
Net Income
$-46.2m
/
Revenue
$7.8m

Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.

Net Margin
-593.8%
=
Net Income
$-46.2m
/
Revenue
$7.8m

Peer Comparison

Country Company Market Cap Net
Margin
IL
InspireMD Inc
NASDAQ:NSPR
69.2m USD
Loading...
JP
Hoya Corp
TSE:7741
8.7T JPY
Loading...
CH
Alcon AG
SIX:ALC
30.9B CHF
Loading...
US
Medline Inc
NASDAQ:MDLN
35.4B USD
Loading...
DK
Coloplast A/S
CSE:COLO B
121.3B DKK
Loading...
US
Align Technology Inc
NASDAQ:ALGN
11.6B USD
Loading...
UK
ConvaTec Group PLC
LSE:CTEC
4.7B GBP
Loading...
KR
HLB Inc
KOSDAQ:028300
8.8T KRW
Loading...
CN
Shenzhen New Industries Biomedical Engineering Co Ltd
SZSE:300832
42.8B CNY
Loading...
CA
Bausch + Lomb Corp
NYSE:BLCO
5.9B USD
Loading...
CH
Ypsomed Holding AG
SIX:YPSN
4.2B CHF
Loading...

Market Distribution

Lower than 93% of companies in Israel
Percentile
7th
Based on 749 companies
7th percentile
-593.8%
Low
-85 210% — -8.6%
Typical Range
-8.6% — 7.2%
High
7.2% — 23 652.1%
Distribution Statistics
Israel
Min -85 210%
30th Percentile -8.6%
Median 1.8%
70th Percentile 7.2%
Max 23 652.1%

InspireMD Inc
Glance View

Market Cap
69.9m USD
Industry
Health Care

InspireMD, Inc. operates as a medical device company, which engages in the development and commercialization of the stent platform technology for the treatment of complex vascular and coronary disease. The firm is focusing on the development and commercialization of its MicroNet stent platform technology for the treatment of vascular and coronary disease. Its MicroNet, a micron mesh sleeve, is wrapped over a stent to provide embolic protection in stenting procedures. Its CGuard carotid embolic prevention system (CGuard EPS) combines its MicroNet and a self-expandable nitinol stent in a single device for use in carotid artery applications. Its MGuard Prime Embolic Protection System (MGuard Prime EPS) is marketed for use in patients with acute coronary syndromes, notably acute myocardial infarction (heart attack) and saphenous vein graft coronary interventions (bypass surgery). The company markets and sells MGuard Prime EPS, a bare-metal cobalt-chromium based stent, for the treatment of coronary disease in the European Union. The company is also developing a neurovascular flow diverter (NGuard), which is an endovascular device.

NSPR Intrinsic Value
HIDDEN
Show
What is Net Margin?
Net Margin shows how much profit a company keeps from each dollar of sales after all expenses, including taxes and interest. It reflects the company`s overall profitability.
How is Net Margin calculated?

Net Margin is calculated by dividing the Net Income by the Revenue.

Net Margin
-593.8%
=
Net Income
$-46.2m
/
Revenue
$7.8m
What is InspireMD Inc's current Net Margin?

The current Net Margin for InspireMD Inc is -593.8%, which is below its 3-year median of -419.6%.

How has Net Margin changed over time?

Over the last 3 years, InspireMD Inc’s Net Margin has decreased from -321.6% to -593.8%. During this period, it reached a low of -593.8% on Sep 30, 2025 and a high of -321% on Dec 31, 2023.

Back to Top